Figure 1.

Pharmacokinetic 2‐compartment models used to describe rituximab pharmacokinetics: linear model with no target‐mediated elimination (model 1), with time‐dependent elimination rate (model 2), with Michaelis–Menten elimination (model 3), with irreversible binding of rituximab to latent target and target turnover (model 4), and irreversible binding of rituximab to latent target with no description of target turnover (model 5). C and L are rituximab concentrations and latent target amount, respectively; V₁ and V₂ are central and peripheral volumes, respectively; CL and Q are systemic and intercompartment clearances, respectively; TME is target‐mediated elimination; CL_T and k_des are initial target‐mediated clearance and its time‐decrease rate constant, respectively; V_M and K_M are maximum rate and Michaelis constant, respectively; k_in, k_out and k_deg are latent target input and output and elimination due to its binding on rituximab, respectively